

Of the negative tests, 1 patient had a false negative T2MR result despite blood cultures growing *C. glabrata*. There was only 1 invalid test in our sample. Thirty-six patients were initiated or maintained on anti-fungal therapy at the time of the T2MR test, with micafungin being the most commonly prescribed anti-fungal agent. Negative T2MR patients had a median anti-fungal therapy duration of 2 days (IQR, 0–16). Sixteen patients (44%) had their anti-fungal therapy discontinued within 1 day of the negative T2MR result. There were no patients with a negative T2MR result who subsequently developed candidemia within 30 days after T2MR testing.

**Conclusion.** Our study showcases the benefit seen with T2MR in curtailing unnecessary anti-fungal exposure. Study limitations include a small cohort and evaluation at a single center. There is an opportunity for this technology to be utilized in anti-fungal stewardship.

**Disclosures.** All authors: No reported disclosures.

### 271. Fungal Diagnostic Studies in Histoplasmosis

Gayathri Krishnan, MD<sup>1</sup>; Margaret Power, BS<sup>1</sup>; J Ryan. Bariola, MD<sup>2</sup> and Ryan K. Dare, MD, MS<sup>1</sup>; <sup>1</sup>University of Arkansas for Medical Sciences, Little Rock, Arkansas; <sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

**Session:** 40. Fungal Diagnostics  
**Thursday, October 3, 2019: 12:15 PM**

**Background.** Histoplasmosis (histo) is a common cause of invasive fungal infection in endemic regions and accurate diagnosis is difficult without direct tissue culture or pathology. Indirect fungal antigen testing for various fungal pathogens is typically performed to assist with diagnostic workup though cross-reaction can lead to difficulty interpreting results. We aimed to evaluate the prevalence of positive antigen testing for non-*Histoplasma* fungal pathogens in patients with proven invasive histo.

**Methods.** We performed a retrospective review of adult patients with proven invasive histo from 2010–2018 at our institution. For inclusion purposes, histo was confirmed by either fungal culture and/or cytology. Patient demographics, clinical characteristics and results of fungal antigen testing for *Histoplasma*, *Blastomyces*, *Aspergillus*, *Cryptococcus* and  $\beta$ -D-glucan were evaluated. Two different urine *Histoplasma* antigen assays were used during the study period.

**Results.** 57 (31%) of 182 patients diagnosed with histo during the study period had culture or cytology evidence of disease and were included in all further analysis. Thirty-two (56%) of these patients were male, 35 (61.4%) were Caucasian and the mean age was 50.1 years. HIV (20; 35%) and being on immunosuppressive medications (21, 37%) were common in this population. The majority of cases were classified as disseminated histo (40, 70%) followed by acute pulmonary (10; 18%) and chronic pulmonary (7, 12%) disease. Results of fungal antigen testing are documented in the table. Chi-squared analysis was performed.

**Conclusion.** There is a frequent cross reaction of non-*Histoplasma* fungal tests in patients with histo. In our review, there was a high rate of cross reaction with *Blastomyces* antigen, which can be confusing in regions where both pathogens coexist. Elevation of  $\beta$ -D-glucan was high in these patients. Urine *Histoplasma* antigen sensitivity was higher with MiraVista testing for disseminated disease in our review. While noninvasive fungal tests are helpful in diagnosis of these infrequent infections, clinicians must still maintain knowledge of the clinical differences between these fungal pathogens and be aware of the limitations of these tests. A prospective study is needed to better define differences between individual *Histoplasma* tests.

### TABLE

TABLE showing results of *Histoplasma* and non-*Histoplasma* urine antigen tests

Histoplasmosis Presentation N=57	Urine <i>Histoplasma</i> Antigen (%)	Urine <i>Blastomyces</i> Antigen (%)	Serum <i>Cryptococcus</i> Antigen (%)	Serum <i>Aspergillus</i> Antigen (%)	Serum Beta D glucan Antigen (%)
Acute pulmonary (n=10) Viracor Miravista* (NS)	4/5 (80) 0/0 (-) 4/5 (80)	1/2 (50)	0/1 (0)	1/4 (25)	0/2 (0)
Chronic Pulmonary (n=7) Viracor Miravista* (NS)	0/4 (0) 0/2 (0) 0/2 (0)	0/4 (0)	0/2 (0)	0/2 (0)	0/2 (0)
Disseminated (n=40) Viracor Miravista* (p=0.019)	26/37 (70) 8/16 (50) 18/21 (86)	25/27 (93)	1/19 (5)	12/20 (60)	21/24 (88)
<b>Total</b> <b>Viracor</b> <b>Miravista (p=0.017)</b>	<b>30/46 (65)</b> <b>8/18 (44)</b> <b>22/28 (79)</b>	<b>26/33 (79)</b>	<b>1/22 (5)</b>	<b>13/26 (50)</b>	<b>21/28 (75)</b>

\* Chi square analysis

**Disclosures.** All authors: No reported disclosures.

### 272. Invasive Pulmonary Aspergillosis: Comparative Analysis in cancer patients with Underlying Hematologic Malignancy vs. Solid Tumor

Rita Wilson Dib, MD<sup>1</sup>; Melissa Khalil, MD<sup>2</sup>; Johny Fares, MD<sup>2</sup>; Dima Dandachi, MD<sup>3</sup>; Ray Y. Hachem, MD<sup>4</sup>; Ying Jiang, MS<sup>4</sup>; Anne-Marie Hajjar Chaftari, MD<sup>5</sup> and Issam I. Raad, MD<sup>2</sup>; <sup>1</sup>Medical College of Georgia Medical Center, Augusta, Georgia; <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, Texas; <sup>3</sup>University of Missouri, Columbia, Missouri; <sup>4</sup>MD Anderson Cancer Center, Houston, Texas; <sup>5</sup>MD Anderson Cancer Center, Houston, Texas

**Session:** 40. Fungal Diagnostics  
**Thursday, October 3, 2019: 12:15 PM**

**Background.** Over the years, the profile of patients with invasive pulmonary aspergillosis (IPA) has extended beyond the commonly associated population with hematologic malignancy (HM) and is now comprising patients with solid tumors and patients with lung diseases. We therefore aimed to compare the clinical characteristics, diagnostic approach and therapeutic outcome of IPA in cancer patients with hematologic malignancies vs. solid tumor (ST).

**Methods.** We conducted a retrospective study evaluating consecutive cases of proven and probable IPA from March 2004 to December 2016 in a tertiary cancer center. We included patients >18 years with an underlying ST, HM, or Hematopoietic Cell Transplantation (HCT) within 1 year of IPA diagnosis.

**Results.** A total of 311 patients were analyzed: 225 had HM including HCT and 86 ST. Patients with ST were more likely to have had COPD (33% vs. 8%,  $P > 0.01$ ) or other underlying pulmonary diseases when compared with HM patients (76% vs. 43%,  $P < 0.01$ ). Radiation therapy prior to the infection was also notably higher in the ST group than the HM group (48% vs. 14%,  $P < 0.01$ ). Patients with HM were more likely to have received steroid (38% vs. 15%,  $P = 0.0001$ ) and have concurrent neutropenia 37% vs. 2%,  $P < 0.0001$ . *A. fumigatus* was most commonly recovered in patients with ST than in patients with HM (66% vs. 38%,  $P < 0.01$ ). Monotherapy and voriconazole-based primary antifungal therapy were more often prescribed in patients with ST than in patients with HM (87% vs. 56%,  $P < 0.0001$  and 77% vs. 53%,  $P = 0.0002$  respectively). Complete or partial successful response to therapy was recorded in 66% of patients with ST compared with 40% in the HM group ( $P = 0.0001$ ). IPA attributable mortality within 12 weeks was significantly higher in the HM than in the ST group (30% vs. 18%,  $P = 0.04$ ).

**Conclusion.** Monotherapy with voriconazole were more often prescribed in patients with ST than in patients with HM. Patients with ST had a better response to antifungal therapy and a lower IPA attributable mortality within 12 weeks compared with those with HM.

**Disclosures.** All authors: No reported disclosures.

### 273. Low Positive Predictive Value of $\beta$ -D-Glucan in Hematology Patients Receiving Antimold Prophylaxis

Eui Jin Chang, MD<sup>1</sup>; Kang Il Jun, MD<sup>1</sup>; Song Mi Moon, MD, PhD<sup>1</sup>; Wan Beom Park, MD, PhD<sup>1</sup>; Ji Hwan Bang, MD, PhD<sup>1</sup>; Eu Suk Kim, MD, PhD<sup>1</sup>; Sang Won Park, MD, PhD<sup>1</sup>; Hong Bin Kim, MD, PhD<sup>2</sup>; Nam-Joong Kim, MD, PhD<sup>3</sup>; Chang Kyung Kang, MD<sup>1</sup> and Myoung-don Oh, MD, PhD<sup>1</sup>; <sup>1</sup>Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Seoul-tukpyolsi, Republic of Korea; <sup>2</sup>Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Kyonggi-do, Republic of Korea

**Session:** 40. Fungal Diagnostics  
**Thursday, October 3, 2019: 12:15 PM**

**Background.** Detection of  $\beta$ -D-glucan (BDG) in serum is recognized as the mycological evidence in the diagnosis of invasive fungal infection (IFI). However, its diagnostic value in low prevalence of IFI has not been elucidated. We aimed to examine the performance of BDG in hematology patients receiving antimold prophylaxis.

**Methods.** We retrospectively reviewed all BDG results performed for the purpose of diagnosis or surveillance for IFI in hematology patients receiving posaconazole or micafungin prophylaxis from January 2017 to February 2019 in a tertiary hospital. At least two consecutive positive results of BDG were regarded as positive BDG. All the episodes were classified into true-positive (TP, positive BDG with probable/proven IFI), true-negative (TN, negative BDG without probable/proven IFI), false-positive (FP, positive BDG without probable/proven IFI), false-negative (FN, negative BDG with probable/proven IFI), and nonevaluable (could not be determined for the occurrence of breakthrough IFI). When BDG test was performed in the setting of persistent fever  $\geq 72$  hours in spite of broad-spectrum antibiotics or with a suspicion of IFI, it was defined as a diagnostic BDG episode, while others were defined as a surveillance BDG episode.

**Results.** Of a total of 140 episodes, 24 episodes were non-evaluable. Among 116 evaluable episodes, 75 received induction chemotherapy for acute leukemia or myelodysplastic syndrome, 35 underwent stem cell transplantation, and 10 had intensive treatment for graft-vs.-host disease. There were three episodes of probable/proven IFI (2.6%). Ninety-one (78.4%) were performed with diagnostic purpose, while 25 (21.6%) were performed for surveillance. TP, TN, FP, and FN were 2 (1.7%), 91, 22, and 1, respectively. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were 66.7%, 80.5%, 8.3% and 98.9%, respectively. PPV was 13.3% and 0% in diagnostic and surveillance BDG episodes, respectively.

**Conclusion.** The PPV of BDG was low in hematology patients receiving antimold prophylaxis, even in the diagnostic-driven episodes. The routine screening of BDG is not helpful, and the BDG test may be used for exclusion of IFI rather than for diagnosis in these patients.

